Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Mobocertinib in Healthy Adults
NCT04441255Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoints: Time to Reach Maximum Plasma Concentration, Maximum Observed Plasma Concentration and 2 more. Started Jul 2020; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04441255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441255.